心筋症治療の世界市場2019-2023

◆英語タイトル:Global Cardiomyopathy Therapies Market 2019-2023
◆商品コード:IRTNTR30336
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月3日
◆ページ数:108
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、心筋症治療の世界市場について調査・分析し、市場概要、市場環境、心筋症治療市場規模、種類別(拡張型心筋症、肥大型心筋症、その他)分析、製品別分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・心筋症治療の世界市場概要
・心筋症治療の世界市場環境
・心筋症治療の世界市場動向
・心筋症治療の世界市場規模
・心筋症治療の世界市場:業界構造分析
・心筋症治療の世界市場:種類別(拡張型心筋症、肥大型心筋症、その他)
・心筋症治療の世界市場:製品別
・心筋症治療の世界市場:地域別市場規模・分析
・心筋症治療の北米市場規模・予測
・心筋症治療のヨーロッパ・中東・アフリカ市場規模・予測
・心筋症治療のアジア太平洋市場規模・予測
・心筋症治療の主要国分析
・心筋症治療の世界市場:意思決定フレームワーク
・心筋症治療の世界市場:成長要因、課題
・心筋症治療の世界市場:競争環境
・心筋症治療の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、AstraZeneca、Merck、Pfizer、Sanofiなどです。
【レポートの概要】

About this market
Advent of genomic medicine to push market growth during the forecast period. Cardiomyopathy is one of the major causes of heart failure. Genomic medicine is an emerging field in healthcare, it uses gene-related information of an individual. Technavio’s analysts have predicted that the cardiomyopathy therapies market will register a CAGR of almost 2% by 2023.
Market Overview
Initiative to increase awareness about disease
There has been an increase in initiatives to spread awareness about cardiomyopathy among people in the last few years.
High cost of treatment
Cardiomyopathy makes it difficult for the heart to pump blood to rest of the body. The condition can be treated by surgically implanting devices within the heart, these devices are quite expensive. This high cost associated with the treatment of cardiomyopathy may pose a challenge to the market.
For the detailed list of factors that will drive and challenge the growth of the cardiomyopathy therapies market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be moderately concentrated and with the presence of several companies including Merck and Sanofi the competitive environment is quite intense. Factors such as the advent of genomic medicine and the initiative to increase awareness about disease, will provide considerable growth opportunities to cardiomyopathy therapies manufactures. AstraZeneca, Merck, Pfizer, and Sanofi are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
• Pipeline analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Dilated cardiomyopathy – Market size and forecast 2018-2023
• Hypertrophic cardiomyopathy – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Market trends
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• Merck
• Pfizer
• Sanofi
PART 15: APPENDIX
• Research methodology
List of abbreviations

Exhibit 01: Years in consideration
Exhibit 02: Global CVD treatment market
Exhibit 03: Segments of global CVD treatment market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Pipeline drugs in late-stage clinical trials
Exhibit 07: Market definition – Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Threat of rivalry
Exhibit 14: Market condition – Five forces 2018
Exhibit 15: Type – Market share 2018-2023 (%)
Exhibit 16: Comparison by type
Exhibit 17: Dilated cardiomyopathy – Market size and forecast 2018-2023 ($ millions)
Exhibit 18: Dilated cardiomyopathy – Year-over-year growth 2019-2023 (%)
Exhibit 19: Hypertrophic cardiomyopathy – Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Hypertrophic cardiomyopathy – Year-over-year growth 2019-2023 (%)
Exhibit 21: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Others – Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by type
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 29: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 31: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 33: Key leading countries
Exhibit 34: Market opportunity
Exhibit 35: Decision framework
Exhibit 36: Impact of drivers and challenges
Exhibit 37: Vendor landscape
Exhibit 38: Landscape disruption
Exhibit 39: Vendors covered
Exhibit 40: Vendor classification
Exhibit 41: Market positioning of vendors
Exhibit 42: AstraZeneca – Vendor overview
Exhibit 43: AstraZeneca – Business segments
Exhibit 44: AstraZeneca – Organizational developments
Exhibit 45: AstraZeneca – Geographic focus
Exhibit 46: AstraZeneca – Key offerings
Exhibit 47: Merck – Vendor overview
Exhibit 48: Merck – Business segments
Exhibit 49: Merck – Organizational developments
Exhibit 50: Merck – Segment focus
Exhibit 51: Merck – Key offerings
Exhibit 52: Pfizer – Vendor overview
Exhibit 53: Pfizer – Business segments
Exhibit 54: Pfizer – Organizational developments
Exhibit 55: Pfizer – Geographic focus
Exhibit 56: Pfizer – Segment focus
Exhibit 57: Pfizer – Key offerings
Exhibit 58: Sanofi – Vendor overview
Exhibit 59: Sanofi – Business segments
Exhibit 60: Sanofi – Organizational developments
Exhibit 61: Sanofi – Segment focus
Exhibit 62: Sanofi – Key offerings
Exhibit 63: Validation techniques employed for market sizing
Exhibit 64: List of abbreviations



【掲載企業】

AstraZeneca、Merck、Pfizer、Sanofi

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[心筋症治療の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆